About C.M.I. Dr. Ciornohuz Adriana
Clinical Trials at C.M.I. Dr. Ciornohuz Adriana
During the past decade, C.M.I. Dr. Ciornohuz Adriana conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at C.M.I. Dr. Ciornohuz Adriana
According to Clinical.Site data, the most researched conditions in "C.M.I. Dr. Ciornohuz Adriana" are
"Psoriatic Arthritis" (2 trials). Many other conditions were trialed in "C.M.I. Dr. Ciornohuz Adriana" in a lesser frequency.
Clinical Trials Intervention Types at C.M.I. Dr. Ciornohuz Adriana
Most popular intervention types in "C.M.I. Dr. Ciornohuz Adriana" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "Apremilast 20mg" (2 trials), "Apremilast 30mg" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.
Clinical Trials Genders at C.M.I. Dr. Ciornohuz Adriana
The vast majority of trials in "C.M.I. Dr. Ciornohuz Adriana" are
2 trials for "All" genders.
Clinical Trials Status at C.M.I. Dr. Ciornohuz Adriana
Currently, there are NaN active trials in "C.M.I. Dr. Ciornohuz Adriana".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in C.M.I. Dr. Ciornohuz Adriana,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in C.M.I. Dr. Ciornohuz Adriana, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".